News
Cipla to break free in US market, may sell products on its own
www.business-standard.com
[Business Standard] - Given Cipla's extensive product repertoire, proven R&D capabilities and extensive manufacturing network, we believe it has all the ingredients to succeed in the US market despite its relatively late entry,” said Nitin Agarwal of IDFC Securities
'Ranbaxy drug pull-out in US shows progress in relations with US FDA'
business-standard.com
[Business Standard] - “Since this withdrawal is part of the implementation of the consent decree and the products were commercially unviable, the financial impact is negligible,” says Nitin Agarwal of IDFC Securities. Besides, the optimism is also triggered by expectations
Spandana's payment overdue crosses Rs cr mark
www.business-standard.com
[Business Standard] - “The Andhra Pradesh Microfinance Institutions (Regulation of Money Lending) Act, has hit the business and the company has failed to collect Rs 1,400 crore from the borrowers in the last two years,” Nitin Agarwal, vice-president (strategy and risk
Nitin Agarwal News | Latest News on Nitin Agarwal - Times of India
timesofindia.indiatimes.com
Check out for the latest news on Nitin Agarwal along with Nitin Agarwal live news at Times of India
sorted by relevance / date